Beigene Ltd (NASDAQ:BGNE) – Research analysts at William Blair issued their Q4 2017 EPS estimates for Beigene in a research note issued to investors on Tuesday, Zacks Investment Research reports. William Blair analyst Y. Xu expects that the company will post earnings of ($1.88) per share for the quarter. William Blair also issued estimates for Beigene’s Q1 2018 earnings at ($2.11) EPS, Q2 2018 earnings at ($2.14) EPS, Q3 2018 earnings at ($2.18) EPS, Q4 2018 earnings at ($1.12) EPS and FY2018 earnings at ($7.56) EPS.
BGNE has been the subject of a number of other research reports. Zacks Investment Research upgraded Beigene from a “hold” rating to a “buy” rating and set a $115.00 price objective for the company in a research note on Tuesday, October 3rd. Maxim Group reaffirmed a “buy” rating and set a $77.00 price target on shares of Beigene in a research report on Monday, September 11th. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price target (up previously from $87.00) on shares of Beigene in a research report on Friday, October 6th. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Tuesday, November 14th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $83.00 price target (up previously from $58.00) on shares of Beigene in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $96.67.
Shares of Beigene (BGNE) traded up $13.50 during trading on Friday, reaching $94.50. The company had a trading volume of 1,747,813 shares, compared to its average volume of 203,371. Beigene has a 1-year low of $26.43 and a 1-year high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.
Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million for the quarter, compared to the consensus estimate of $1.55 million. During the same quarter last year, the company posted ($1.08) EPS.
In other Beigene news, CEO John Oyler sold 85,906 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $84.66, for a total value of $7,272,801.96. Following the sale, the chief executive officer now owns 332,697 shares of the company’s stock, valued at approximately $28,166,128.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Jane Huang sold 600 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $85.00, for a total value of $51,000.00. Following the completion of the sale, the chief marketing officer now directly owns 264,900 shares in the company, valued at approximately $22,516,500. The disclosure for this sale can be found here. Insiders have sold a total of 284,299 shares of company stock worth $23,432,132 in the last three months. 19.90% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in BGNE. Hillhouse Capital Management Ltd. increased its position in shares of Beigene by 172.6% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after purchasing an additional 2,355,906 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in Beigene during the 3rd quarter worth approximately $62,076,000. Janus Henderson Group PLC bought a new position in Beigene during the 3rd quarter worth approximately $33,744,000. Alliancebernstein L.P. bought a new position in Beigene during the 2nd quarter worth approximately $7,373,000. Finally, Employees Retirement System of Texas bought a new position in Beigene during the 2nd quarter worth approximately $2,855,000. Hedge funds and other institutional investors own 55.34% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/04/beigene-ltd-bgne-expected-to-post-q4-2017-earnings-of-1-88-per-share.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Get a free copy of the Zacks research report on Beigene (BGNE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.